肝动脉灌注羟基喜树碱合并栓塞治疗原发性肝癌

Hepatic arterial embolization and chemotherapy with HPT-containing regimen for the treatment of advanced primary liver cancer

目的 :观察以羟基喜树碱 (HPT)为主的化疗药经肝动脉灌注合并栓塞治疗中、晚期原发性肝癌的疗效。方法 :采用HPT、吡柔比星、卡铂或 5 -氟脲嘧啶与碘化油联合经肝动脉灌注栓塞 ,治疗不能手术的中、晚期肝癌 41例。结果 :41例患者共接受10 2次介入治疗。部分缓解 2 1例 ,稳定 16例 ,进展 4例 ,总有效率 5 1.2 %。 30例患者血清AFP≥ 2 0 0 μg·L-1,经治疗后 2 2例AFP明显下降或恢复正常。生存率 6个月为 87.2 % ,1年 5 8.1% ,2年 19.0 %。不良反应主要为骨髓抑制 (Ⅰ～Ⅲ 度 )和消化道反应 (Ⅰ～Ⅱ度 )。结论 :肝动脉灌注以HPT为主的药物合并栓塞治疗中、晚期肝癌 ,疗效好 ,毒副反应小。

Objective:[WT5BZ]To evaluate the curative effect of hepatic artery embolization and chemotherapy with HPT-Containing regimen in the treatment of nonresectable primary liver cancer(PLC).[WT5HZ]Methods:[WT5BZ]41 patients with advanced PLC were treated by transcatheter arterial embolization combined with intraarterial infusion with a mixture of Hydroxycamptothecin(HPT),Pirarubicirn(THP),Carboplatin(CBP) or 5-fluorouracil(5-Fu)lipiodol.[WT5HZ]Results:[WT5BZ]41 patients received 102 courses.Partial response was observed in 21 patients with an overall response rate of 51.2%.The frequency of marked decrease of serum α-fetoprotein concentrations was 73%(22/30).The total 6-month,1-year and 2-year survival rates were 87.2%,58.1% and 19.0% respectively.The major toxicities were myelosuppression and digestive tract reaction.[WT5HZ]Conclusion:[WT5BZ]Transcatheter artery chemoembolization with HPT-Containing regimen may achieve favorable results in the treatment of nonresectabel PLC.The toxicties are tolerable. [WT5HZ]